menu
    • menu
    [{"orgOrder":0,"company":"Curatis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pamapimod","moa":"p38\/Mapk","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curatis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Not Applicable"},{"orgOrder":0,"company":"Curatis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pamapimod","moa":"p38\/Mapk","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Curatis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Curatis \/ Not Applicable"},{"orgOrder":0,"company":"Curatis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pamapimod","moa":"p38\/Mapk","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Curatis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Not Applicable"},{"orgOrder":0,"company":"Curatis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pamapimod","moa":"p38\/Mapk","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Curatis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Not Applicable"},{"orgOrder":0,"company":"Curatis","sponsor":"Great Health Companion Group Ltd","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Pamapimod","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Curatis \/ Great Health Companion Group Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Great Health Companion Group Ltd"},{"orgOrder":0,"company":"Curatis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pamapimod","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Curatis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Not Applicable"},{"orgOrder":0,"company":"Curatis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pamapimod","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Curatis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Not Applicable"},{"orgOrder":0,"company":"Curatis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pamapimod","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curatis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Curatis \/ Not Applicable"},{"orgOrder":0,"company":"Curatis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pamapimod","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curatis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Not Applicable"},{"orgOrder":0,"company":"Curatis","sponsor":"ChaoDian","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Pamapimod","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curatis \/ ChaoDian","highestDevelopmentStatusID":"6","companyTruncated":"Curatis \/ ChaoDian"},{"orgOrder":0,"company":"Curatis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Not Applicable","leadProduct":"C-PBTE-01","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Curatis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Curatis \/ Not Applicable"},{"orgOrder":0,"company":"Curatis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"C-PTBE-01","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Curatis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Curatis \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Curatis

    Menu

    Curatis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Curatis

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Curatis

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : C-PTBE-01

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Curatis Plans USA Biologic License for C-PTBE-01 to Extend Market Protection

                            Details : Curatis is focusing its development activities for C-PTBE-01 on an very rare group of aggressive brain tumours (Diffuse Midline Glioma, DMG).

                            Brand Name : C-PTBE-01

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 14, 2024

                            Lead Product(s) : C-PTBE-01

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Curatis

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Curatis

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : C-PBTE-01

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Curatis Submits Orphan Drug Application in U.S. for Lead Candidate

                            Details : Curatis is focusing its development activities for C-PTBE-01 on an extremely rare group of aggressive brain tumours (diffuse midline glioma) in children.

                            Brand Name : C-PBTE-01

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            August 27, 2024

                            Lead Product(s) : C-PBTE-01

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Curatis

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Curatis

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pamapimod,Pioglitazone

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : ChaoDian

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kinarus Therapeutics Signed CHF1.5 Million Convertible Loan Agreement With ChaoDian (Hangzhou) Investment Mana...

                            Details : The agreement forms the basis for discussions on the introduction, development and commercialization of KIN001, a patented combination of two APIs, pamapimod and pioglitazone, for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in China.

                            Brand Name : KIN001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 10, 2023

                            Lead Product(s) : Pamapimod,Pioglitazone

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : ChaoDian

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Curatis

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Curatis

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pamapimod,Pioglitazone

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update

                            Details : KIN001 is a patented combination of pamapimod, a highly selective investigational small molecule inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), and pioglitazone, a marketed drug for the treatment of type 2 diabetes.

                            Brand Name : KIN001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 21, 2023

                            Lead Product(s) : Pamapimod,Pioglitazone

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Curatis

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Curatis

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pamapimod,Pioglitazone

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan

                            Details : KIN001 is an orally administered combination of pamapimod and pioglitazone. Pamapimod is a p38 MAPK inhibitor, whereas pioglitazone is a PPAR gamma activator. It is currently being developed in COVID-19, Idiopathic Pulmonary Fibrosis and wet Age-Related ...

                            Brand Name : KIN001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 16, 2023

                            Lead Product(s) : Pamapimod,Pioglitazone

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Curatis

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Curatis

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pamapimod

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and...

                            Details : KIN001 is an orally available patented combination of pamapimod, a highly selective investigational small molecule inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), and pioglitazone, a marketed drug for the treatment of type 2 diabetes.

                            Brand Name : KIN001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 06, 2022

                            Lead Product(s) : Pamapimod

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Curatis

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Curatis

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pamapimod,Pioglitazone

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001

                            Details : KIN001 is combination of two APIs: pamapimod and pioglitazone. Kinarus has found that combining pamapimod with pioglitazone, leads to synergistic efficacy and increased duration of action in preclinical models of wet AMD, IPF and fibrotic and inflammator...

                            Brand Name : KIN001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 22, 2022

                            Lead Product(s) : Pamapimod,Pioglitazone

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Curatis

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Curatis

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pamapimod,Pioglitazone

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Great Health Companion Group Ltd

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China

                            Details : KIN001 is a patented combination of two active pharmaceutical ingredients (APIs): pamapimod and pioglitazone. Pamapimod is a highly selective clinical stage small molecule inhibitor of the p38 MAP kinase signaling pathway.

                            Brand Name : KIN001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 16, 2022

                            Lead Product(s) : Pamapimod,Pioglitazone

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Great Health Companion Group Ltd

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Curatis

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Curatis

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pamapimod,Pioglitazone

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kinarus Therapeutics Initiates KIN001 Phase II KINFAST Clinical Trial in COVID-19 Outpatients

                            Details : KIN001 is an orally administered combination of two drugs that have demonstrated synergistic antiviral and anti-inflammatory activity, as well as ability to reduce tissue fibrosis.

                            Brand Name : KIN001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 29, 2022

                            Lead Product(s) : Pamapimod,Pioglitazone

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Curatis

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Curatis

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pamapimod,Pioglitazone

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kinarus Therapeutics to Hold Webinar on a New Approach to Treating COVID-19

                            Details : KIN001 (pamapimod) is a proprietary novel combination of two active pharmaceutical ingredients that have demonstrated synergistic antiviral and anti-inflammatory activity, as well as ability to reduce tissue fibrosis in preclinical studies.

                            Brand Name : KIN001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 22, 2022

                            Lead Product(s) : Pamapimod,Pioglitazone

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth